Recently, Alkermes refocused on neuroscience, and now it’s dealing with stabilizing revenues from core products like Lybalvi, Vivitrol, Aristada, and Vumerity. However, the main growth driver ...

Alkermes derives revenues from the net sales of its proprietary products — Vivitrol (alcohol and opioid dependence), Aristada (schizophrenia) and Lybalvi (schizophrenia and bipolar I disorder ...

For our mature products, VIVITROL and ARISTADA, we expect flat to modest growth, and for our most recently launched product, LYBALVI, continued growth and uptake in those markets. We will take you ...